Molecular predictors of chemotherapy response in non-small-cell lung cancer

References

• Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin.55, 10–30 (2005).
   PubMed Web of Science ®Google Scholar
• Johnson BE. Second lung cancers in patients after treatment for an initial lung cancer. J. Natl Cancer Inst.90, 1335–1345 (1998).
   PubMedGoogle Scholar
• Kelly K, Crowley J, Bunn PA Jr et al. Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol.19, 3210–3218 (2001).
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med.346, 92–98 (2002).
   PubMed Web of Science ®Google Scholar
• Kosmidis P, Mylonakis N, Nicolaides C et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a Phase III randomized trial. J. Clin. Oncol.20, 3578–3585 (2002).
   PubMed Web of Science ®Google Scholar
• Rosell R, Gatzemeier U, Betticher DC et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann. Oncol.13, 1539–1549 (2002).
   PubMed Web of Science ®Google Scholar
• Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol.21, 3016–3024 (2003).
   PubMed Web of Science ®Google Scholar
• Gridelli C, Gallo C, Shepherd FA et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a Phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.21, 3025–3034 (2003).
   PubMed Web of Science ®Google Scholar
• Smit EF, van Meerbeeck JP, Lianes P et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a Phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group – EORTC 08975. J. Clin. Oncol.21, 3909–3917 (2003).
   PubMed Web of Science ®Google Scholar
• Georgoulias V, Papadakis E, Alexopoulos A et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet357, 1478–1484 (2001).
   PubMed Web of Science ®Google Scholar
• Laack E, Dickgreber N, Muller T et al. Randomized Phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J. Clin. Oncol.22, 2348–2356 (2004).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol.18, 2095–2103 (2000).
   PubMed Web of Science ®Google Scholar
• Fossella FV, DeVore R, Kerr RN et al. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol.18, 2354–2362 (2000).
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol.22, 1589–1597 (2004).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350, 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science304, 1497–1500 (2004).
   PubMed Web of Science ®Google Scholar
• Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer – molecular and clinical predictors of outcome. N. Engl. J. Med.353, 133–144 (2005).
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N. Engl. J. Med.355, 2542–2550 (2006).
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol.22, 2184–2191 (2004).
   PubMed Web of Science ®Google Scholar
• Bepler G, Sharma S, Cantor A et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J. Clin. Oncol.22, 1878–1885 (2004).
   PubMed Web of Science ®Google Scholar
• Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med.355, 983–991 (2006).
   PubMed Web of Science ®Google Scholar
• Bepler G, Kusmartseva I, Sharma S et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J. Clin. Oncol.24, 4731–4737 (2006).
   PubMed Web of Science ®Google Scholar
• Bjorklund S, Skog S, Tribukait B et al. S-phase-specific expression of mammalian ribonucleotide reductase R1 and R2 subunit mRNAs. Biochemistry29, 5452–5458 (1990).
   PubMed Web of Science ®Google Scholar
• Elledge SJ, Zhou Z, Allen JB. Ribonucleotide reductase: regulation, regulation, regulation. Trends Biochem. Sci.17, 119–123 (1992).
   PubMed Web of Science ®Google Scholar
• Reichard P. From RNA to DNA, why so many ribonucleotide reductases? Science260, 1773–1777 (1993).
   PubMed Web of Science ®Google Scholar
• Filatov D, Ingemarson R, Johansson E et al. Mouse ribonucleotide reductase: from genes to proteins. Biochem. Soc. Trans.23, 903–905 (1995).
   PubMed Web of Science ®Google Scholar
• Tonin PN, Stallings RL, Carman MD et al. Chromosomal assignment of amplified genes in hydroxyurea-resistant hamster cells. Cytogenet. Cell Genet.45, 102–108 (1987).
   PubMedGoogle Scholar
• Stubbe J. Ribonucleotide reductases in the twenty-first century. Proc. Natl Acad. Sci. USA95, 2723–2724 (1998).
   PubMed Web of Science ®Google Scholar
• Fan H, Huang A, Villegas C et al. The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. Proc. Natl Acad. Sci. USA94, 13181–13186 (1997).
   PubMed Web of Science ®Google Scholar
• Gautam A, Li ZR, Bepler G. RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene22, 2135–2142 (2003).
   PubMed Web of Science ®Google Scholar
• Tamura M, Gu J, Matsumoto K et al. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science280, 1614–1617 (1998).
   PubMed Web of Science ®Google Scholar
• Tamura M, Gu J, Danen EH et al. PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway. J. Biol. Chem.274, 20693–20703 (1999).
   PubMed Web of Science ®Google Scholar
• Bepler G, Gautam A, McIntyre LM et al. Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J. Clin. Oncol.20, 1353–1360 (2002).
   PubMed Web of Science ®Google Scholar
• Davidson JD, Ma L, Flagella M et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res.64, 3761–3766 (2004).
   PubMed Web of Science ®Google Scholar
• Rosell R, Danenberg KD, Alberola V et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res.10, 1318–1325 (2004).
   PubMed Web of Science ®Google Scholar
• Reed E. Platinum–DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat. Rev.24, 331–344 (1998).
   PubMed Web of Science ®Google Scholar
• Sancar A. Mechanisms of DNA excision repair. Science266, 1954–1956 (1994).
   PubMed Web of Science ®Google Scholar
• Mu D, Hsu DS, Sancar A. Reaction mechanism of human DNA repair excision nuclease. J. Biol. Chem.271, 8285–8294 (1996).
   PubMed Web of Science ®Google Scholar
• Zamble DB, Mu D, Reardon JT et al. Repair of cisplatin–DNA adducts by the mammalian excision nuclease. Biochemistry35, 10004–10013 (1996).
   PubMed Web of Science ®Google Scholar
• Altaha R, Liang X, Yu JJ et al. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int. J. Mol. Med.14, 959–970 (2004).
   PubMed Web of Science ®Google Scholar
• Dabholkar M, Vionnet J, Bostik-Bruton F et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Invest.94, 703–708 (1994).
   PubMed Web of Science ®Google Scholar
• Lord RV, Brabender J, Gandara D et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res.8, 2286–2291 (2002).
   PubMed Web of Science ®Google Scholar
• The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med.350, 351–360 (2004).
   PubMed Web of Science ®Google Scholar
• Simon GR, Sharma S, Cantor A et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest127, 978–983 (2005).
   PubMed Web of Science ®Google Scholar
• Ceppi P, Volante M, Novello S et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann. Oncol.17, 1818–1825 (2006).
   PubMed Web of Science ®Google Scholar